Kazia advances paxalisib colorectal cancer program
Kazia Therapeutics (NASDAQ:KZIA) reported preclinical data showing its PI3K/mTOR inhibitor paxalisib reduced tumor burden by 52% in an MSS/pMMR colorectal cancer model.
Kazia Therapeutics (NASDAQ:KZIA) reported preclinical data showing its PI3K/mTOR inhibitor paxalisib reduced tumor burden by 52% in an MSS/pMMR colorectal cancer model.
Comstock Resources (NYSE:CRK) signed a binding letter of intent with SOCAR for the sale of non-operated working interests in its Legacy and Western Haynesville upstream assets and a 15% stake in Pinnacle Gas Services for $1.65 billion in cash.
Descartes Systems Group (NASDAQ:DSGX) acquired Extensiv, a California-based provider of AI-enabled warehouse management and omnichannel fulfillment solutions, for approximately $120 million.
Kazia Therapeutics (NASDAQ:KZIA) reported preclinical results showing its PI3K/mTOR inhibitor paxalisib produced antitumor activity when combined with standard therapies in HR+/HER2- breast cancer models.
RedHill Biopharma (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq from Ferring Pharmaceuticals in a transaction focused on expanding its gastrointestinal business.
Adicet Bio (NASDAQ:ACET) completed the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis.
Bunge Global (NYSE:BG) agreed to sell its two sugarcane mills in São Paulo, Brazil, to COFCO International as part of the company’s strategic business priorities.
AstraZeneca (NASDAQ:AZN) completed its exclusive license agreement with Dizal Pharmaceutical for worldwide rights to develop and commercialize ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for patients with lung cancer.
Medtronic (NYSE:MDT) reported first quarter fiscal 2027 revenue of $9.756 billion, up 13.7% year over year on both reported and organic bases, including an estimated $570 million benefit from an additional fiscal week.
MiniMed (NASDAQ:MMED) reported first quarter fiscal 2027 net sales of $843 million, increasing 16.6% year over year on a reported basis and 15.8% organically.
GET YOUR GRAFA EDGE NOW
Sign up free to unlock this feature
We'll switch on a 30-day Edge trial as a welcome gift